Drug intelligence / Profile preview

RNA-lipoplex prostate cancer vaccine

Development stage
Unknown
Lead developer
BioNTech
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

The RNA-lipoplex prostate cancer vaccine is an investigational mRNA-based immunotherapy developed by Ahvaz Jundishapur University of Medical Sciences. It utilizes an RNA-lipoplex (liposome) delivery system for intravenous administration, encoding three specific prostate cancer-associated antigens: prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and six-transmembrane epithelial antigen of the prostate 1 (STEAP1). The vaccine is designed to stimulate a systemic T-cell-mediated immune response against tumor cells expressing these antigens. It is currently being evaluated in Phase I clinical trials for the treatment of prostate cancer.

Other names
RNA-liposome prostate cancer vaccine
02

Targets

P fimbriaePSMA (Prostate-specific membrane antigen)STEAP1 (Six-transmembrane epithelial antigen of prostate 1)PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on RNA-lipoplex prostate cancer vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-lipoplex prostate cancer vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call